Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9313982 | 0.84 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2LMNAL3MBTL1KMT2A | |
| SCHEMBL10827291 | 0.83 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2LMNAL3MBTL1KMT2A | |
| SCHEMBL28421108 | 0.83 | CYP19A1 (0.58) | ALDH1A1SMN1; SMN2KMT2AGAAKDM4E | |
| SCHEMBL30430689 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAL3MBTL1KMT2A | |
| SCHEMBL5216927 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAL3MBTL1KMT2A | |
| SCHEMBL28205036 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAL3MBTL1KMT2A | |
| SCHEMBL8948339 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAL3MBTL1KMT2A | |
| SCHEMBL28520217 | 0.81 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2LMNAL3MBTL1KMT2A | |
| SCHEMBL14828702 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAL3MBTL1GAAPOLB | |
| SCHEMBL28049857 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAL3MBTL1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4303216-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-01-10 | — | — | EP | disclosed |
| CN-116981661-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20230218612-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2023-07-13 | — | — | US | disclosed |
| WO-2022184152-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-09-09 | — | — | WO | disclosed |
| US-11267826-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200179376-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| EP-3630783-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| US-20100261929-A1 | PROCESS AND APPARATUS FOR PRODUCTION OF CYANOHYDRIN COMPOUND, AND PROCESS FOR PRODUCTION OF ALPHA-HYDROXYESTER COMPOUND | NIPPOH CHEMICALS CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100256409-A1 | PROCESS FOR PRODUCTION OF CYANOHYDRIN COMPOUND, AND PROCESS FOR PRODUCTION OF ALPHA HYDROXYESTER COMPOUND | NIPPOH CHEMICALS CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2213657-A1 | PROCESS AND APPARATUS FOR PRODUCTION OF CYANOHYDRIN COMPOUND, AND PROCESS FOR PRODUCTION OF ALPHA -HYDROXYESTER COMPOUND | Nippoh Chemicals Co., Ltd (JP) | 2010-08-04 | — | — | EP | disclosed |
| EP-2213656-A1 | PROCESS FOR PRODUCTION OF CYANOHYDRIN COMPOUND, AND PROCESS FOR PRODUCTION OF ALPHA-HYDROXYESTER COMPOUND | Nippoh Chemicals Co., Ltd (JP) | 2010-08-04 | — | — | EP | disclosed |
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179376-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | ALDH1A1 2390/4885SMN1; SMN2 4325/4885LMNA 4578/4885 |
| US-11267826-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | ALDH1A1 2794/4885SMN1; SMN2 3101/4885LMNA 3468/4885 |
| US-20230218612-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | ALDH1A1 2390/4885SMN1; SMN2 4325/4885LMNA 4578/4885 |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | ALDH1A1 208/4885SMN1; SMN2 4263/4885LMNA 2547/4885 |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | ALDH1A1 2794/4885SMN1; SMN2 3101/4885LMNA 3468/4885 |
| US-20100261929-A1 | PROCESS AND APPARATUS FOR PRODUCTION OF CYANOHYDRIN COMPOUND, AND PROCESS FOR PRODUCTION OF ALPHA-HYDROXYESTER COMPOUND | HPD, HAAO, PCCA | ALDH1A1 1000/4885SMN1; SMN2 4396/4885LMNA 2196/4885 |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | ALDH1A1 264/4885SMN1; SMN2 4221/4885LMNA 2226/4885 |
| US-20100256409-A1 | PROCESS FOR PRODUCTION OF CYANOHYDRIN COMPOUND, AND PROCESS FOR PRODUCTION OF ALPHA HYDROXYESTER COMPOUND | HPD, CYP8B1, PCCA | ALDH1A1 733/4885SMN1; SMN2 4445/4885LMNA 1831/4885 |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, HASPIN | ALDH1A1 3571/4885SMN1; SMN2 4568/4885LMNA 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.